These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 22150535)
21. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. Harris MS; Lichtenstein GR Aliment Pharmacol Ther; 2011 May; 33(9):996-1009. PubMed ID: 21385194 [TBL] [Abstract][Full Text] [Related]
22. Mesalazine for ulcerative colitis complicated with diabetic nephropathy. Oshimoto H; Okamura S; Onozato Y; Ishihara H; Mori M J Gastroenterol; 2001 Dec; 36(12):863-4. PubMed ID: 11777217 [No Abstract] [Full Text] [Related]
23. Combined butyric acid/mesalazine treatment in ulcerative colitis with mild-moderate activity. Results of a multicentre pilot study. Assisi RF; Minerva Gastroenterol Dietol; 2008 Sep; 54(3):231-8. PubMed ID: 18614971 [TBL] [Abstract][Full Text] [Related]
24. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Kruis W; Kiudelis G; Rácz I; Gorelov IA; Pokrotnieks J; Horynski M; Batovsky M; Kykal J; Boehm S; Greinwald R; Mueller R; Gut; 2009 Feb; 58(2):233-40. PubMed ID: 18832520 [TBL] [Abstract][Full Text] [Related]
25. Methodological Approach to Mesalazine Treatment in Patients with Mild-to-moderate Ulcerative Colitis. Agilli M; Dogan T; Ergin G Inflamm Bowel Dis; 2015 Aug; 21(8):E14-5. PubMed ID: 26083615 [No Abstract] [Full Text] [Related]
26. Reply to Methodological Approach to Mesalazine Treatment in Patients with Mild-to-moderate Ulcerative Colitis. Pedersen N; Munkholm P Inflamm Bowel Dis; 2015 Aug; 21(8):E15-6. PubMed ID: 26111214 [No Abstract] [Full Text] [Related]
27. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. Tang T; Targan SR; Li ZS; Xu C; Byers VS; Sandborn WJ Aliment Pharmacol Ther; 2011 Jan; 33(2):194-202. PubMed ID: 21114791 [TBL] [Abstract][Full Text] [Related]
28. [Rescue therapy with sulfasalazine prior to immunosuppressive or biological agents in ulcerative colitis poorly controlled with mesalazine]. Martínez González J; Busto Bea V; Mesonero Gismero F; Parejo Carbonell S; Garrido E; López San Román A Gastroenterol Hepatol; 2013 Jan; 36(1):7-10. PubMed ID: 23195755 [TBL] [Abstract][Full Text] [Related]
29. [Maintaining remission of ulcerative colitis with the probiotic Escherichia Coli Nissle 1917 is as effective as with standard mesalazine]. Adam B; Liebregts T; Holtmann G Z Gastroenterol; 2006 Mar; 44(3):267-9. PubMed ID: 16514573 [No Abstract] [Full Text] [Related]
30. Encapsulated mesalamine granules (Apriso) for ulcerative colitis. Med Lett Drugs Ther; 2009 May; 51(1312):38-9. PubMed ID: 19448588 [TBL] [Abstract][Full Text] [Related]
31. Once daily 5-aminosalicylic acid for the treatment of ulcerative colitis; are we there yet? Lakatos PL; Lakatos L Pharmacol Res; 2008; 58(3-4):190-5. PubMed ID: 18801439 [TBL] [Abstract][Full Text] [Related]
32. New desensitization regimen with mesalamine granules in a patient with ulcerative colitis and mesalamine intolerance. Oustamanolakis P; Koutroubakis IE Inflamm Bowel Dis; 2011 Feb; 17(2):E8-9. PubMed ID: 20848496 [No Abstract] [Full Text] [Related]
33. Experience with Eudragit-S-coated mesalamine (Asacol) in inflammatory bowel disease. An open study. Faber SM; Korelitz BI J Clin Gastroenterol; 1993 Oct; 17(3):213-8. PubMed ID: 8228082 [TBL] [Abstract][Full Text] [Related]
34. Optimized Management of Ulcerative Proctitis: When and How to Use Mesalazine Suppository. Kato S; Ishibashi A; Kani K; Yakabi K Digestion; 2018; 97(1):59-63. PubMed ID: 29393142 [TBL] [Abstract][Full Text] [Related]
35. eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis. Pedersen N; Thielsen P; Martinsen L; Bennedsen M; Haaber A; Langholz E; Végh Z; Duricova D; Jess T; Bell S; Burisch J; Munkholm P Inflamm Bowel Dis; 2014 Dec; 20(12):2276-85. PubMed ID: 25248002 [TBL] [Abstract][Full Text] [Related]
36. Recurrence of myocarditis after mesalazine treatment for ulcerative colitis: a case report. Sabatini T; Filippini A; Nicosia F; Preti S; Bertoli M Inflamm Bowel Dis; 2013 Mar; 19(3):E46-8. PubMed ID: 22517473 [No Abstract] [Full Text] [Related]
37. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis. Munakata A; Yoshida Y; Muto T; Tsuchiya S; Fukushima T; Hiwatashi N; Kobayashi K; Kitano A; Shimoyama T; Inoue M J Gastroenterol; 1995 Nov; 30 Suppl 8():108-11. PubMed ID: 8563868 [TBL] [Abstract][Full Text] [Related]
39. Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. Forbes A; Al-Damluji A; Ashworth S; Bramble M; Herbert K; Ho J; Kang JY; Przemioslo R; Shetty A Aliment Pharmacol Ther; 2005 May; 21(9):1099-104. PubMed ID: 15854171 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: a double-blinded and randomized study. Gong Y; Zha Q; Li L; Liu Y; Yang B; Liu L; Lu A; Lin Y; Jiang M J Ethnopharmacol; 2012 Jun; 141(2):592-8. PubMed ID: 21911045 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]